Filing Flows › Insulet (PODD) › Q3 2025
Insulet (PODD) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 6, 2025
Insulet (PODD) reported revenue of $706M for the third quarter 2025 (Q3 2025), +30% from a year earlier and +9% from the quarter before. Operating margin was 16.7%, net earnings $87.6M (12.4% of revenue).
Insulet, Q3 2025: revenue $706M (+30% year over year), operating margin 16.7%, net earnings $87.6M, operating cash flow $126M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $706M | +9% | +30% |
| Gross profit | $510M | +13% | +35% |
| Operating profit | $118M | -3% | +34% |
| Net earnings | $87.6M | +289% | +13% |
| Operating cash flow | $126M | -36% | +16% |
| Free cash flow | $100M | -44% | +23% |
What changed
Revenue was $706.3M in Q3 2025, up 30% year over year and up 9% from the previous quarter. U.S. was the largest line at 70% of revenue. U.S. added $101.5M year over year (up 26%), 62% of the total change. Drug Delivery declined 31%.
Gross margin was 72.2%, up 2.9 points from a year earlier. Operating profit was $117.7M, a 16.7% margin (up 0.5 points year over year). Of the extra revenue versus a year earlier, 18% reached operating profit, above the 16% margin then. Operating expenses grew 36% against revenue growth of 30%. The fastest-growing cost line was Research & development (+41%). Net earnings were $87.6M, up 13% year over year. The effective tax rate was 28.7%.
Operating cash flow was $125.7M (up 16% year over year), 143% of net earnings. Non-cash charges added back $22.0M of depreciation and amortization and $16.7M of share-based compensation. Capital expenditures of $25.6M left free cash flow of $100.1M.
Questions
What was Insulet's revenue in the third quarter 2025?
Insulet (PODD) reported revenue of $706M for the third quarter 2025 (Q3 2025), +30% from a year earlier and +9% from the quarter before.
Was Insulet profitable in the third quarter 2025?
Operating profit was $118M (16.7% of revenue) and net earnings $87.6M.
Source: Insulet 10-Q on SEC EDGAR.